Livongo Partners with Prognos Health to Drive More Personalized Health Nudges™ with Clinical Laboratory Analytics at Scale
09 Abril 2020 - 9:00AM
Livongo Health, Inc. (Nasdaq: LVGO), the leading Applied Health
Signals company empowering people with chronic conditions to live
better and healthier lives, today announced that it has partnered
with Prognos Health, an AI-driven platform company focused on
predicting the trajectory of disease to drive precise actions
earlier in the Member journey, to infuse Livongo’s platform with
harmonized clinical lab based insights. Livongo Members can now
share their test results from leading commercial laboratories with
Livongo on an opt-in basis.
Prognos Health has the largest registry of
clinical diagnostics information across over 50 conditions, with
billions of medical records for over 250 million people. Clinical
laboratory tests, including blood glucose levels, HbA1c, lipids,
and creatine, are important health markers and risk indicators for
people with chronic conditions and given there is no
standardization for lab data, the data is often missing critical
information. Prognos enriches lab data by applying
clinically-driven technologies at scale. By partnering with
Prognos, Livongo now offers Members the ability to easily view
their important clinical laboratory data on the Livongo platform.
In addition, Livongo’s AI+AI® engine is now powered by lab test
values, delivering Members more personalized telehealth coaching
interactions and Health Nudges™.
“As COVID-19 continues to strain our healthcare
system, limiting in-person doctor and hospital visits and offering
people, always at their option, virtual and comprehensive care
through remote monitoring is vital,” said Livongo President
Dr. Jennifer Schneider, M.D., M.S. “By aggregating clinical labs
data, Livongo Members can access more of their important health
information in one convenient location and receive personalized
digital and virtual coaching that cares for the whole person.”
During program registration, Livongo Members who
have chronic condition related lab test results are automatically
notified of the opportunity to allow Livongo to access those
results; further personalizing their Livongo experience. Members
have full control over this feature and can change their lab test
results sharing permissions at any time.
“As the consumer digital health market leader,
we are excited to partner with Livongo given our shared commitment
to improving chronic health conditions by leveraging deep clinical
insights,” said Prognos Health Co-Founder and Chief Executive
Officer, Sundeep Bhan. "Lab results are the leading indicator of a
Member’s health and integrating our lab-based insights will drive
more personalized interactions and empower Livongo’s Members to
improve their outcomes."
As of March 2, 2020, Livongo has more than 800
clients, including more than 30 percent of Fortune 500 companies,
four of the top seven health plans, health systems, government
organizations, labor unions, and the two largest pharmacy benefit
managers as partners. A 2019 study conducted in collaboration with
Eli Lilly and Company demonstrated that 94 percent of Livongo for
Diabetes program Members who completed a program survey achieved
improved Diabetes Empowerment Scale – Short Form (DES-SF) or
Diabetes Distress Scale 2 (DDS2) in year one of the Livongo for
Diabetes Program; effectively improving confidence in diabetes
self-management while decreasing burnout related to diabetes
management.
About Prognos Health
Prognos Health is an AI platform company focused
on predicting the trajectory of disease to drive decisions earlier
in healthcare in collaboration with payers, life sciences and
providers. The Prognos Registry is the largest source of clinical
diagnostics information in 50 disease areas, with nearly billions
of medical records for hundreds of millions of patients. Prognos
has over 1,000 extensive proprietary and learning clinical
algorithms to enable earlier patient identification for enhanced
treatment decision-making, risk management and quality improvement.
The company’s investors include Safeguard Scientifics, Inc., Merck
Global Health Innovation Fund, Cigna, GIS Strategic Ventures, Hikma
Ventures, Hermed Capital, and Maywic Select Investments. Learn more
about Prognos at www.prognoshealth.com.
About Livongo
Livongo empowers people with chronic conditions
to live better and healthier lives, beginning with diabetes and now
including hypertension, weight management, diabetes prevention, and
behavioral health. Livongo pioneered the category of Applied Health
Signals to offer Members clinically-based insights that focus on
the whole person and make it easier to stay healthy. Using its
AI+AI® engine, Livongo’s team of data scientists aggregate and
interpret substantial amounts of health data and information to
create actionable, personalized, and timely health signals
delivered to Livongo Members exactly when and where they need them.
The Livongo approach delivers better clinical and financial
outcomes while creating a different and better experience for
people with chronic conditions. For more information, visit:
www.livongo.com or engage with Livongo
on LinkedIn or Twitter.
Livongo Media Contact:
Jake Mazankepress@livongo.com630-640-5253
Livongo Investor Contact:
John
HallockInvestor-relations@livongo.com617-615-7712
Livongo Health (NASDAQ:LVGO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Livongo Health (NASDAQ:LVGO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024